Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Science translational medicine - 26 Aug 2015

Garcia-Murillas Isaac, Schiavon Gaia, Weigelt Britta, Ng Charlotte, Hrebien Sarah, Cutts Rosalind J, Cheang Maggie, Osin Peter, Nerurkar Ashutosh, Kozarewa Iwanka, Garrido Javier Armisen, Dowsett Mitch, Reis-Filho Jorge S, Smith Ian E, Turner Nicholas C

Abstract excerpt

The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor DNA (ctDNA) in plasma can be used to monitor for minimal residual disease (MRD) in breast cancer. In a prospecti...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm, Residual

Share to Precision Medicine

Share to Recurrence

Source

Identifiers

PMID: 26311728
DOI: 10.1126/scitranslmed.aab0021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26311728-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.PMID 26311728Read ↗

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.Semantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read ↗

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Semantic proximity Read ↗

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerSemantic proximity Read ↗

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionSemantic proximity Read ↗

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.